Genzyme Europe B.V.

Genzyme is committed to discovering and delivering transformative therapies for patients with rare and special unmet medical needs, providing hope where there was none before. Genzyme has pioneered the development and delivery of transformative therapies for over 30 years. Founded in 1981 in Boston, Massachusetts, Genzyme evolved from a tiny start-up with just a handful of employees to one of the world's leading biotech companies. Acquired by Sanofi in 2011, Genzyme now benefits from the reach and resources of one of the world’s largest pharmaceutical companies, with a shared commitment to improving the lives of patients. Genzyme has long been known for their expertise in the class of rare genetic diseases known as lysosomal storage disorders (LSDs). LSDs remain the heart of their company today, but they have also expanded – through both in-house development and strategic acquisitions and partnerships – to other disease areas such as thyroid cancer and multiple sclerosis. Driven by their commitment to patients, they strive to develop strong relationships with patient communities and listen to their perspectives so that they can truly understand their needs. These collaborations guide them as they continue to push the boundaries of medicine and technology to develop new and better therapies where none existed before. As the specialty care global business unit of Sanofi, they are focused on rare diseases, multiple sclerosis, immunology, and oncology. More than 30 years since they began, they remain just as committed to and passionate about advancing therapies that offer hope to patients and families. Their approach is shaped by a long history of developing highly specialized treatments and forging close relationships with physician and patient communities. Founded as Genzyme in Boston in 1981, they rapidly grew to become one of the world’s leading biotechnology companies, recognized for their pioneering development of treatments for rare genetic disorders and their innovative contributions to medical science and biomanufacturing. Genzyme became part of Sanofi in 2011. While continuing to focus on rare diseases, they also established theirselves as a leader in the field of multiple sclerosis. In 2016, their focus expanded to include Sanofi’s programs in oncology and immunology.